定做假的马绍尔群岛护照,【telegram:十852 55367074】（whatsApp:+852 55367074）办理定做假的马绍尔群岛护照,购买定做假的马绍尔群岛护照,定制定做假的马绍尔群岛护照,出售定做假的马绍尔群岛护照,办理定做假的马绍尔群岛护照多少钱『真实办护照，可根据客户样本制版印刷』可加急 ,【telegram:+852 55367074】【WHATSApp:+852 55367074】『办理驾驶证、身份证id、居留证、各种证明，发货速度快。』 联系我们【飞机\whatsapp 同号:+852 55367074】定做假的马绍尔群岛护照,定做假的马绍尔群岛护照,定做假的马绍尔群岛护照 On the morning of March 26, the official WeChat public account of the Institute of Microbiology of the Chinese Academy of Sciences announced that on March 24, the world-famous medical journal "The Lancet-Infectious Diseases" reported the results of the Phase 1 and Phase 2 clinical trials of the recombinant protein subunit vaccine (ZF2001) developed by Academician Gao Fu's team and Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. (referred to as "Zhifei Long Kema").The trial results show that the vaccine is safe and there are no serious adverse events related to the vaccine. 97% of the participants who received 3 doses of 25 渭g vaccine produced neutralizing antibodies that can block live viruses. The level of neutralizing antibodies exceeded the serum of recovered patients.Zhifei Longkoma is a wholly-owned subsidiary of the listed company Chongqing Zhifei Biological Products Co., Ltd. (Zhifei Biological Products, 300122).On October 29, 2020, Zhifei Biotech announced that its recombinant COVID-19 vaccine had completed Phase I and II clinical trials and obtained key data on safety and immunogenicity.The Institute of Microbiology of the Chinese Academy of Sciences stated that the recombinant protein subunit vaccine has the advantages of high yield, high safety, easy storage and transportation, and is one of the important options to prevent and block the spread of COVID-19.According to the Institute of Microbiology of the Chinese Academy of Sciences, the two-phase clinical trial of the ZF2001 vaccine in China recruited a total of 950 healthy adults aged 18 to 59. It adopted a randomized, double-blind and placebo-controlled trial protocol. The trial was completed at the Second Affiliated Hospital of Chongqing Medical University, Beijing Chaoyang Hospital of Capital Medical University and the Hunan Xiangtan Center for Disease Control and Prevention.The trial evaluates the safety and immunogenicity of the vaccine, including adverse events and serious adverse events, antibody titers, neutralizing antibody titers, and seroconversion rates.In terms of effectiveness, after 2 doses of ZF2001 vaccine, 76% of people can produce neutralizing antibodies.After 3 doses of vaccine, 97% of people can produce neutralizing antibodies.The geometric mean titer (GMT) of the antibody reached 102.5, exceeding the neutralizing antibody level in the sera of 89 recovered COVID-19 patients.In addition, the vaccine can produce a moderate and balanced Th1/Th2 cellular immune response. In terms of safety, most participants did not observe adverse reactions or had mild or moderate adverse reactions, such as redness and swelling, pain at the injection site, itching, etc., which are common reactions after vaccination with recombinant protein vaccines.No vaccine-related serious adverse events occurred.It is worth noting that in February this year, Gao Fu鈥檚 team at the Chinese Center for Disease Control and Prevention released some results of the ongoing international phase 3 clinical trial on bioRxiv, showing the neutralizing effect of the domestic recombinant protein subunit COVID-19 vaccine ZF2001 on the new South African variant (501Y.V2).Currently, ZF2001 is undergoing international multi-center Phase 3 clinical trials in Uzbekistan, Indonesia, Pakistan and Ecuador, and was approved for registration in Uzbekistan on March 1, 2021. It is the world's first approved recombinant protein vaccine for COVID-19.Domestically, the vaccine also received emergency use approval on March 10. 颖桥百黄倩鼐鞠尚俣壮卮腺刳时案